Angiotec

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angiotec

Property Description
Active ingredient Enalapril Maleate
Form Oral tablet
Pharmacological class Angiotensin-Converting Enzyme Inhibitor (ACE Inhibitor)
Common use Cardiovascular support
Origin Synthetic, Prodrug

Angiotec: An Overview of the Angiotensin-Converting Enzyme Inhibitor

Angiotec is a specific prescription-only medication containing the active chemical substance Enalapril Maleate. It is classified as an Angiotensin-Converting Enzyme Inhibitor (ACE Inhibitor), a core pharmacological class for systemic cardiovascular support. This classification is widely clinically recognized for influencing the body's internal hormonal systems that regulate vascular tension.

This medication is supplied as a long-acting oral tablet. ACE Inhibitors are distinguished by their specific mode of action within the complex system that regulates blood pressure, placing them centrally in modern therapeutic strategies for supporting cardiovascular efficiency.


What is Enalapril and Why is it Considered a Prodrug?

Its active ingredient, Enalapril, is designated as a prodrug, which means the compound is pharmacologically inactive upon ingestion. Angiotec requires bioconversion (chemical change) in the body, primarily in the liver, to transform it into its powerful active metabolite, Enalaprilat. Enalapril is rapidly absorbed and hydrolyzed to the active metabolite Enalaprilat; the body must process the pill to activate its therapeutic effect.

The oral tablet is the solid dosage form, and while the Enalapril Maleate is the active component, pharmaceutical excipients are required to create the stable formulation suitable for the oral route of administration and subsequent metabolism.


Angiotec's General Role in Cardiovascular Support

The general purpose of Angiotec is to promote vasodilation and reduce systemic vascular resistance, thereby lessening the strain placed on the heart. It achieves this by inhibiting the enzyme responsible for creating Angiotensin II, a potent substance that constricts blood vessels.

By blocking this conversion, Angiotec effectively suppresses the Renin-Angiotensin-Aldosterone System (RAAS). This action not only encourages the relaxation and widening of the arteries but also indirectly helps normalize fluid balance by decreasing the hormone Aldosterone, which encourages salt and water retention. The overarching benefit is a more efficient circulatory system.

Regulatory References

  1. National Library of Medicine (MedlinePlus)

What side effects are possible with Angiotec?

Possible Side Effects and Safety Information

The safety profile for Angiotec (Enalapril Maleate) details adverse reactions organized by frequency and the physiological system affected, as classified in official regulatory documents. This information focuses strictly on officially documented risks and limitations.


Frequency-Classified Adverse Reactions

The most frequently reported reactions in clinical use include cough, headache, dizziness, and fatigue, all classified as common. Hypotension (low blood pressure), including orthostatic effects, is also common and often observed following initial administration. Rare adverse reactions include serious conditions like Angioedema (swelling of the face, tongue, or throat), pancreatitis, and hepatic failure (liver dysfunction).


System-Organ-Class Safety Groups

Adverse effects are formally grouped by the system-organ classes they affect. Common effects include those related to the Nervous System (dizziness, headache), Respiratory System (cough), Vascular System (hypotension), and Gastrointestinal System (nausea, diarrhea). The drug's safety profile also lists effects on the Renal and Urinary Disorders, Hepato-biliary Disorders, and Blood and Lymphatic Systems (e.g., anemia).


Safety Constraints and Considerations

Angiotec is formally contraindicated for individuals with a history of angioedema related to a previous ACE inhibitor or those with hereditary or idiopathic angioedema. A critical restriction is its contraindication during the second and third trimesters of pregnancy due to the risk of fetal injury. The official label also notes that excessive hypotension is most likely to occur following the initial dose, particularly in patients with pre-existing volume depletion.

Overdose and Emergency Response

The official regulatory documentation for Angiotec (Enalapril Maleate) details specific manifestations and required emergency actions in case of overdose. The most prominent documented clinical presentation is profound hypotension, which can rapidly progress to circulatory shock, reflecting an exaggerated pharmacological effect. Other recognized clinical signs include bradycardia or tachycardia, along with central nervous system effects such as dizziness, stupor, and somnolence.

The regulatory labeling highlights potential severe outcomes, including the onset of acute renal failure and the development of the electrolyte abnormality hyperkalemia.

Emergency Action Required (Regulatory Mandates) Documentation Notes
Seek immediate medical attention This action is mandated for any suspected or symptomatic overdose, particularly when profound hypotension is evident.
Hospital Monitoring Required for patients to observe for the persistence of symptoms and progression to severe outcomes.
No specific antidote is known This is the confirmed regulatory statement regarding reversal agents.
Supportive Treatment Management is symptomatic, including volume expansion via intravenous infusion for hypotension. Hemodialysis is documented as effective for removing the active metabolite, Enalaprilat, in cases where overdose is severe.

Furthermore, population-specific notes indicate that patients with pre-existing renal impairment may require enhanced care due to the risk of prolonged active metabolite concentrations following an overdose. Continuous monitoring of vital signs and laboratory values is required during observation.

Therapeutic Uses of Angiotec

What Angiotec Treats: Main Uses and Benefits

The primary therapeutic role of Angiotec is to manage conditions where the circulatory system is under chronic strain. The medication provides supportive assistance across several key therapeutic areas.

Angiotec is commonly used as a foundation for long-term hypertension (high blood pressure) management, and also addresses chronic conditions like symptomatic heart failure and asymptomatic heart dysfunction, and may contribute to supporting stability in conditions where symptoms may intensify temporarily. Furthermore, it is considered relevant for use in high-risk patients with diabetes and hypertension to assist with supporting long-term kidney function. Its use is relevant for easing the overall symptom load that creates noticeable physiological strain, which may help reduce the risk of major adverse cardiovascular events.

“This medication is applied in scenarios where additional management of discomfort is required to support functional stability.”

Therapeutic Focus

The medication is commonly used to help manage symptoms related to excessive fatigue and shortness of breath during physical activity. It assists with maintaining physical stability in situations where patients experience symptomatic discomfort, and may help lower the likelihood of hospitalization in cardiac patients.


Quick Fact: Supports Management of Systemic Pressure

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Angiotec? Official Regulatory Information

The eligibility profile for Angiotec (Enalapril Maleate) is strictly defined by government regulatory documents, focusing on patient status, age, and comorbidities.


Populations for Whom Use is Contraindicated

Angiotec is contraindicated (absolutely prohibited) for several groups:

  • Patients with a prior history of angioedema related to any ACE inhibitor, or hereditary/idiopathic angioedema.
  • Women during the second and third trimesters of pregnancy due to the risk of fetal injury and death.
  • Patients receiving a neprilysin inhibitor (e.g., sacubitril/valsartan), requiring a mandatory 36-hour wash-out period.
  • Patients with severe hepatic impairment or severe renal impairment (creatinine clearance < 10 mL/min).

Age and Conditional Eligibility

Age Group / Condition Regulatory Status
Adults Established for use in all labeled indications.
Pediatric Patients Established for hypertension in children geq one month of age. Not recommended for neonates.
First Trimester Pregnancy Not recommended.
Renal Function Not recommended for severe impairment; use requires caution in non-severe cases.

Eligibility is defined by regulatory criteria, not clinical advice, ensuring that individuals with specific physiological states or co-medications are excluded from use.

What should I know about interactions with other medicines?

Angiotec Interactions with other medicines and products

The interaction profile of Angiotec (Enalapril Maleate) is formally documented in government regulatory labeling, establishing specific restrictions and required constraints for co-administration.

Interaction Classifications

Classification Interacting Agents (Examples) Constraint/Official Outcome
Contraindicated Sacubitril/Valsartan Do not use; a 36-hour washout period is mandatory when switching between these agents.
Contraindicated Aliskiren (Direct Renin Inhibitor) Prohibited in patients with diabetes mellitus or moderate to severe renal impairment (GFR <60 ml/min/1.73 m^2).

Pharmacodynamic and Exposure Interactions

  • Potassium-Sparing Diuretics, Supplements, and Salt Substitutes: Co-administration with agents like Spironolactone or Potassium Supplements is associated with an increased risk of hyperkalemia (elevated serum potassium levels).
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Use of NSAIDs, including selective COX-2 inhibitors, may lead to the deterioration of renal function, a risk particularly noted in the elderly or those with compromised renal function.
  • Lithium: Angiotec is officially documented to increase serum lithium concentrations and the risk of toxicity by reducing lithium's renal clearance.
  • Alcohol: Consumption of alcohol may increase the risk of side effects related to hypotension.
  • Food: Regulatory information confirms that the absorption of Enalapril is not influenced by food in the gastrointestinal tract.

The resulting interaction structure is primarily defined by the risks of dual RAAS blockade, hyperkalemia, and the documented reduction in the renal clearance of co-administered Lithium.

Mechanism of Action

Angiotec is a high-affinity antagonist that selectively binds to the Receptor Activator of NF-kappaB Ligand (RANKL) and blocks its interaction with the Receptor Activator of NF-kappaB (RANK) on the surface of osteoclast precursor cells and mature osteoclasts.

This binding inhibits the downstream signaling cascade that is necessary for osteoclast formation, activation, and survival. The blockade of the RANK/RANKL axis leads to a decreased rate of osteoclastogenesis and increased apoptosis of existing osteoclasts.

The resulting mechanism modulates the balance in favor of bone formation over resorption through inhibition of osteoclast-mediated bone matrix resorption. Angiotec's physicochemical properties facilitate localized activity, restricting its primary effect to the bone microenvironment.

Dosage and Administration Information

How Angiotec is Used: Official Administration Guidelines

Angiotec (Enalapril Maleate) is prescribed as an oral tablet for long-term management, with administration protocols established for proper usage.

Standard Dosage Regimens for Adults

Standard instructions specify distinct starting and maximum doses based on the condition being addressed.

Therapeutic Indication Starting Dose Maximum Daily Dose
Hypertension 5 mg once daily (qDay) 40 mg
Heart Failure/LV Dysfunction 2.5 mg twice daily (BID) 40 mg

Frequency and Administration Context

Dose Titration: Treatment commonly begins with a low dose that is gradually increased (titrated) over a period of two to four weeks until the optimal maintenance dose is achieved. The total daily dose may be administered once or split into two doses, depending on the condition being treated.

Relation to Food: The tablet can be taken with or without food without affecting its absorption.

Special Conditions: The initial dose for heart failure must be administered under close medical supervision to monitor the body's initial response. Furthermore, for patients with impaired kidney function (e.g., Creatinine Clearance le 30 mL/min), a lower starting dose of 2.5 mg daily is required.

Tablet Use: If a tablet has a score line, this is intended only to facilitate breaking for ease of swallowing and should not be used to divide the tablet for dosage accuracy, unless explicitly stated for that strength.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Angiotec

The research surrounding Angiotec (Enalapril Maleate) includes large clinical trials and long-term observational studies. This body of evidence explores how the medication influences specific measurements and outcomes related to systemic cardiovascular health and its chronic conditions. Studies help show what has been observed in specific patient groups so far, providing context but not individual predictions.


Evidence for Use in High Blood Pressure Management

Angiotec was studied for the management of high blood pressure, a condition characterized by chronic physiological strain on the cardiovascular system. Research has explored its role in long-term chronic management.

The available evidence includes Randomized Controlled Trials (RCTs) and long-term cohort studies that monitored effects over extended observation periods. These studies examined measurements related to the reduction and control of systolic and diastolic blood pressure (Systemic Pressure) in general adult populations. Findings describe patterns observed in the studies regarding the achievement and maintenance of blood pressure parameters over long periods, consistent with a therapy intended for chronic use.


Evidence in Support of Chronic Heart Conditions

The research base for Angiotec in chronic heart conditions includes large Randomized, Double-Blind, Placebo-Controlled Trials that explored both symptomatic and asymptomatic phases of heart dysfunction.

Study Outcomes for Symptom Management

For symptomatic heart failure, studies examined populations already experiencing noticeable physiological strain and physical discomfort. Research monitored outcomes related to functional status and daily functioning or activity level, including measurements of excessive fatigue and shortness of breath during physical activity. Trials reported patterns in the incidence of hospitalization for heart failure and described how symptoms evolved in the observed populations, which contributes to the broader evidence landscape for chronic heart condition management.

Research on Asymptomatic Left Ventricular Dysfunction

Research also included prevention trials focusing on clinically stable patients who had no prior symptoms of heart failure but did have evidence of left ventricular dysfunction. These studies monitored the rate of transition to conditions involving periods of heightened symptoms and examined outcomes monitoring physiological strain or stress over follow-up periods that extended up to five years. The findings describe group patterns related to the onset of symptoms in this specific prevention-focused cohort.


What is Still Uncertain About Angiotec Research

While Angiotec has an established history, transparent research practice requires acknowledging remaining uncertainties:

  • Subgroup Findings are Uncertain: Data for certain groups remain insufficient, or findings were mixed, particularly when comparing outcomes in various racial or ethnic groups or in very elderly or pediatric populations.
  • Long-Term Effects are Not Fully Established: While follow-up durations were substantial in several key studies, findings do not determine whether an individual will respond similarly over decades, and data for outcomes beyond the initial clinical trial timeframe are often observational.

Key Studies & References

  1. Enalapril Maleate: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Angiotec (FAQ)

Q: How long does Angiotec take before you notice a difference?

Regulatory documents state that the activity to lower blood pressure (antihypertensive effect) usually begins within about one hour after the tablet is taken orally. The maximum reduction in blood pressure is typically achieved between four to six hours after administration. This information helps describe the expected timing of the drug's activity in the body.

Q: Do I need to stop Angiotec gradually, or can I stop suddenly?

Official documents indicate that abrupt withdrawal of Angiotec has generally not been associated with a rapid rise in blood pressure for most study participants. However, Angiotec is intended for chronic cardiovascular support, and the decision to stop or change treatment is a medical one. Patients are strictly advised not to discontinue treatment on their own.

Q: Is Angiotec considered a 'blood thinner'?

No, Angiotec is classified by regulatory authorities as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This class of medication works primarily to reduce resistance in the blood vessels (vasodilation) and lower systemic pressure. Its purpose is to support cardiovascular function, not to 'thin' the blood like anticoagulant medications.

Q: Can Angiotec affect sleep patterns?

Official product information notes that sleep-related changes are possible, although they are not among the most common effects. Adverse reactions reported in regulatory documents include both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness).

Q: Can Angiotec cause muscle cramps or joint pain?

Muscle cramps are listed in official safety documents as a less common or uncommon adverse reaction associated with this medication. Other joint or muscle issues are not cited among the frequent or common side effects listed in core regulatory sections.

Q: Why does Angiotec need to be taken at the same time every day?

The drug is designed to maintain its blood pressure-lowering effect (antihypertensive effect) for at least 24 hours at recommended doses. Taking the tablet around the same time each day is generally considered a practice that supports the maintenance of a continuous therapeutic effect.

Q: Is Angiotec available as a generic medicine?

Yes, the active ingredient in Angiotec, Enalapril Maleate, is widely available as a generic medicine. Regulatory databases, such as the FDA Orange Book, list numerous manufacturers who have approved generic versions of this drug.

Q: Does Angiotec have a 'black box' warning in the official documentation?

Yes, the FDA Prescribing Information includes a Boxed Warning (the agency’s strongest warning) concerning Fetal Toxicity. This warning states that medicines that affect the renin-angiotensin system, like Angiotec, can cause injury and even death to a developing fetus during the second and third trimesters of pregnancy.

Q: How quickly does the effect of Angiotec wear off?

The time it takes for the drug's activity to diminish is described using the effective half-life of its active substance, Enalaprilat. After multiple doses, the effective half-life for the active metabolite is approximately 11 hours. This measure describes the rate at which the body eliminates the drug's active form.

Q: Is Angiotec known to cause skin rashes?

Yes, official product information lists rash as one of the reported adverse reactions. This is a general term for skin eruption and is noted in the safety profile.

Q: Does Angiotec cause any sensitivity to the sun?

Yes, photosensitivity (an increased sensitivity to sunlight that can result in an exaggerated sunburn or rash) is reported as a potential adverse reaction in regulatory documents.

Q: Why is it recommended to check bloodwork while taking Angiotec?

Official warnings detail the risks of elevated serum potassium levels (hyperkalemia) and potential changes in kidney function. Therefore, medical professionals typically monitor blood parameters, such as potassium and creatinine levels, to detect and manage these risks.

Q: Can Angiotec affect driving ability?

Official product information includes warnings that adverse reactions like dizziness and fatigue (tiredness) may occur, particularly after the first dose or after increasing the dose. These effects could potentially impair the ability to drive or operate machinery.

Q: Are there common mental or mood changes noted with Angiotec?

Yes, official safety documentation reports that adverse reactions can include depression and confusion. These are generally categorized as effects related to the central nervous system.

Q: Is it true that Angiotec can cause kidney problems?

The official label notes that Impaired Renal Function (kidney function problems) is a potential risk associated with this medication. Official labeling indicates that patients with pre-existing kidney issues are often prescribed a lower starting dose and generally require careful medical monitoring during treatment.

Q: Can Angiotec be taken by people with diabetes?

Regulatory information does not prohibit the use of Angiotec in all patients with diabetes. However, official safety documentation strictly contraindicates (prohibits) the use of Angiotec when taken at the same time as the drug Aliskiren in patients with diabetes, due to an increased risk of kidney issues.

Q: Are there long-term side effects that official documents mention for Angiotec?

The official safety documents list all reported adverse reactions by their frequency, but they do not explicitly categorize them as only 'long-term' or 'short-term' effects. Patients are instructed to report any ongoing or new adverse events to their healthcare provider.

Q: Can older people safely take Angiotec?

Use in older patients is established for the labeled indications. However, caution is advised because the dose may require adjustment based on the individual's kidney function, which is often naturally reduced in older populations. The risk of kidney deterioration when combined with non-steroidal anti-inflammatory drugs (NSAIDs) is specifically noted in the elderly population.

Q: What specific ingredients are in Angiotec besides the main drug?

Angiotec contains the active component, Enalapril Maleate. In addition to the active ingredient, regulatory documents list various inactive ingredients (known as excipients) that are required to form the tablet, such as lactose, magnesium stearate, and starch.

Q: Can men and women use Angiotec for the same conditions?

Official regulatory indications for use, such as for high blood pressure and heart conditions, do not differentiate between men and women. The only gender-specific restriction is the strict contraindication (prohibition) for use during the second and third trimesters of pregnancy due to the risk of fetal injury.

Q: Is there any evidence about Angiotec use during pregnancy or breastfeeding?

Official warnings clearly state that Angiotec is contraindicated during the second and third trimesters of pregnancy due to significant risk to the fetus. Regulatory information also confirms that both the drug (Enalapril) and its active form (Enalaprilat) are secreted into human milk in small amounts.

Q: Can taking Angiotec affect my liver tests?

Regulatory safety information reports rare cases of serious liver dysfunction (hepatic failure). If a patient develops signs like jaundice (yellowing of the skin/eyes) or has a significant increase in hepatic enzymes (as measured by liver tests), official documentation notes that medical professionals typically consider discontinuing the drug in such circumstances.

Q: Is it possible to be allergic to Angiotec?

Yes, Angiotec is strictly contraindicated (prohibited) for anyone with a history of a severe reaction called angioedema (swelling of the face, tongue, or throat) from any previous ACE inhibitor. The drug is also prohibited for patients with hereditary or unexplained angioedema.

Q: Can Angiotec be split or crushed, according to the label?

Regulatory patient counseling information states that if the tablet has a score line, it is intended only to make the tablet easier to swallow. Official patient counseling information specifies that the score line is generally not intended for precise dosage division, but rather for ease of swallowing, unless specific instructions have been given by a medical professional. The official label does not provide instruction regarding crushing the tablet.

How should Angiotec be stored and disposed of?

How to Store and Dispose of Angiotec (Enalapril Maleate)

The official labeling mandates specific conditions for storing Angiotec tablets to maintain their stability.

Storage Requirements

Angiotec must be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). It is essential to protect the tablets from moisture and to ensure they are not frozen. The medicine must be kept in its original container and the container should remain tightly closed when not in use. As with all medications, Angiotec must be stored out of the sight and reach of children.

Disposal Instructions

To protect the environment, unused or expired Angiotec tablets should not be disposed of via wastewater (such as flushing down the toilet) or household waste. The correct procedure is to dispose of the product according to a pharmacist's guidance or through local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angiotec found in:

A-Z Index: